This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

DosingDosingIBRANCE® Dosing
 
Monitoring Requirements
SafetySafetyIBRANCE® Safety ProfileNeutropeniaAdverse Event ManagementClinical Trials
Clinical TrialsIBRANCE® Clinical TrialsIBRANCE® PALOMA-2 Trial
 
IBRANCE® PALOMA-3 Trial
Real World EvidenceReal World EvidenceIBRANCE® Real World EvidenceIRIS (UK) StudyROIS
 
P-REALITY X
Patient ProfilesThe Ibrance® PatientPatient ProfilesAlison - >65 years with comorbiditiesBecky - Postmenopausal with bone-only diseaseELEVATE TVSupport and ResourcesSupport and ResourcesIBRANCE Service SupportMaterials
 
Videos

The content of this website has been produced in line with the IBRANCE® Summary of Product Characteristics for the UK. IBRANCE® (palbociclib) Prescribing Information for the UK click here.  Adverse event reporting information can be found at the bottom of the page.

Example

Welcome to ELEVATE TV, a promotional medical education programme - developed and funded by Pfizer Ltd - where healthcare professionals can enhance their knowledge on metastatic breast cancer (mBC). 

ELEVATE is underpinned by three core pillars of Education, Evidence, and Experience. ELEVATE is an educational and interactive forum where leading faculty members and other healthcare professionals discuss topics at the forefront of mBC management. All content on ELEVATE TV originates from Pfizer's ELEVATE masterclass programme and is presented on this page as bite-size, on demand videos. 


The IBRANCE (palbociclib) section features a variety of ELEVATE masterclasses led by experts in mBC. 

Video content hub: 


Cardio-Oncology for Breast Cancer Patients 


Dr Alex Lyon  

Consultant Cardiologist Clinical Lead in Cardio-Oncology Royal Brompton Hospital 

 

Dr Alex Lyon presents Cardiovascular toxicity prevention and management and European society of Cardiology guidelines.

To access the resource from the video click here.

 

[18 min 8 seconds]

 

Case study: Treatment in bone - specific metastases 


Dr Andrew Proctor 

Consultant Medical Oncologist, York and Scarborough Teaching Hospital NHS Foundation Trust 

 

Dr Proctor presents a case study of a post-menopausal patient with mBC and extensive bone metastases.

 

[15 min 9 seconds]

Case study: Bone-only metastases

Dr John Conibear 
Consultant Clinical Oncologist at Bart's Health NHS Trust, London


Dr Conibear presents a case study of a patient with de-novo bone-only mBC.

[6 min 45 seconds]


Panel Discussion: What do you think will have the biggest impact on the evolving mBC landscape in the next 5 years?

In this video the ELEVATE 2024 Faculty present their views on future advances in mBC treatment. The discussion panel consisted of Prof. Stephen Johnston (UK), Prof. Hope Rugo (USA), Dr Javier Cortes (Spain) Dr Alicia Okines (UK), and Dr Caroline Michie (UK) 

[8 min 45 seconds] 


ELEVATE 2025 Event overview

In this video Prof. Stephen Johnston and Dr Jenny Smith give an overview of the ELEVATE 2025 in-person meeting. 

[4 min 35 seconds] 

mBC : metastatic Breast Cancer

PP-IBR-GBR-6412. May 2025

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2025 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-11245. January 2025
You are now leaving PfizerPro​​​​​

You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024.

YesNo
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​